Ataluren

Ataluren
Clinical data
Trade names	Translarna
Other names	PTC124
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth
ATC code	M09AX03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); EU: Rx-only;
Identifiers
	IUPAC name 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid;
CAS Number	775304-57-9 ;
PubChem CID	11219835;
IUPHAR/BPS	7341;
DrugBank	DB05016;
ChemSpider	9394889 ;
UNII	K16AME9I3V;
KEGG	D09323 ;
ChEBI	CHEBI:94805;
ChEMBL	ChEMBL256997 ;
CompTox Dashboard (EPA)	DTXSID5046776 ;
ECHA InfoCard	100.132.097
Chemical and physical data
Formula	C15H9FN2O3
Molar mass	284.246 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc3ccccc3c1nc(no1)c2cc(ccc2)C(=O)O;
	InChI InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20) ; Key:OOUGLTULBSNHNF-UHFFFAOYSA-N ;
	(what is this?)

Ataluren, sold under the brand name Translarna, is a medication for the treatment of Duchenne muscular dystrophy. It was designed by PTC Therapeutics.

^ Cite error: The named reference UKlabel was invoked but never defined (see the help page).
^ Cite error: The named reference Translarna EPAR was invoked but never defined (see the help page).